Before joining TheStreet in March 2001, Feuerstein covered business software for Upside.com. Prior to that he covered a variety of business beats, including technology and commercial real estate, at the San Francisco Business Times.
Feuerstein graduated from Emory University with a bachelor's degree in political science.
Recent Articles By The Author
Global Blood, FDA Reach Agreement on Pivotal Trial Design for Sickle Cell Disease Drug
Global Blood wants to start screening sickle cell disease patients for the phase III study in December with the hope of having top-line results in the first half of 2019.
Alkermes Depression Drug Finds Success on Third Study Attempt
Third time was the charm for Alkermes' experimental antidepressant ALKS 5461.
Gilead Sciences Advances Fatty Liver Drug, Causing Some Head-Scratching
Gilead is under enormous pressure from investors to acquire companies or develop new drugs from its pipeline.
Puma Bio's Desperate Money Grab Signals Breast Cancer Drug Trouble
Puma CEO Alan Auerbach wanted the cash desperately, regardless of Puma's stock price. Get the deal done, even if you have to sell it to the shorts.
Celgene Skips the Placebo, Fails Drug Development 101
Celgene is not some dinky micro-cap biotech lacking the resources or knowledge to conduct a rigorous clinical trial, so omitting a placebo arm from the GED-0301 study is inexcusable.